Relevance of angiogenesis in neuroendocrine tumors

Targeted Oncology

Volumn 7, Issue 2, 2012, Pages 93-98

  Teulé, Alexandre ^a   Casanovas, Oriol ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Angiogenesis; Molecular target; Neuroendocrine tumor; Sunitinib

Indexed keywords

AF 493 NA; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BETA INTERFERON; BEVACIZUMAB; CAPECITABINE; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; MINOCYCLINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AF 493 NA; MONOCLONAL ANTIBODY DC101; OCTREOTIDE; OXALIPLATIN; PAZOPANIB; PEGINTERFERON ALPHA2B; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RECOMBINANT ENDOSTATIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL PROLIFERATION; CONTINUOUS INFUSION; DRUG RESPONSE; DRUG TOLERANCE; ENZYME INHIBITION; HUMAN; INSULINOMA; LYMPHOCYTOPENIA; MICROVASCULATURE; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NONHUMAN; OPPORTUNISTIC INFECTION; PERICYTE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR BLOOD FLOW; TUMOR REGRESSION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 84865783751     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0217-x     Document Type: Review

References (45)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072
2. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Fléjou J, Degott C (1998) Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopa-thology 32:133-138 (Pubitemid 28126179)
3. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Canc Cell 8:299-309 (Pubitemid 41443415)
4. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92(1):94-101 (Pubitemid 40188441)
5. Marion-Audibert AM, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle JA, Partensky C, Scoazec JY (2003) Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125:1094-1104 (Pubitemid 37193456)
6. Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F, Ruszniewski P, Bedossa P (2008) Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res 14:6634-6639
7. Konstantinova I, Lammert E (2004) Microvascular development: learning from pancreatic islets. Bioessays 26:1069-1075 (Pubitemid 39424810)
8. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812 (Pubitemid 29291347)
9. Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115-122 (Pubitemid 15064530)
10. Parangi S, Dietrich W, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D et al (1995) Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumor-igenesis in a transgenic model of islet cell carcinoma. Cancer Res 55:6071-6076
11. Varker KA, Campbell J, Shah MH (2008) Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Canc Chemother Pharmacol 61:661-668
12. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroen-docrine tumors. J Clin Oncol 24(3):401-406 (Pubitemid 46630459)
13. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS (2006) Phase II study of recombinant human endostatin in patients with advanced neuroen-docrine tumors. J Clin Oncol 24(22):3555-3561 (Pubitemid 46630526)
14. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced an-giogenesis suppresses tumour growth in vivo. Nature 362:841-844 (Pubitemid 23132159)
15. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, Aftab DT, McDonald DM (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discovery 2(3):270-287
16. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC (2007) Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109(8):1478-1486 (Pubitemid 46595681)
17. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26:1316-1323
18. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt JA, Attawia M, Lawrence C, Fuchs CS (2006) A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 24(18S):4044 (June 20 Supplement)
19. Kunz PL, Kuo T, Zahn JM, Kaiser HL, Norton JA, Visser BC, Longacre TA, Ford JM, Balise RR, Fisher GA (2010) A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol 28:15s, suppl; abstr 4104
20. Venook AP, Ko AH, Tempero MA, Uy J, Weber T, Korn M, Bergsland EK (2008) Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 26:15s, suppl; abstr 15545
21. Franco M, Roswall P, Cortez E, Hanahan D, Pietras K (2011) Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 118 (10):2906-2917
22. Bergers G, Song S, Meyer-Morse N et al (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295 (Pubitemid 36554699)
23. Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangio-genic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939-952 (Pubitemid 46202314)
24. Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469-1473 (Pubitemid 36418403)
25. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513
26. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26(20):3403-3410
27. Hobday TJ, Rubin J, Holen K, et al. (2007) MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 25:18s, suppl; abstr 4504
28. Pavel ME, Bartel C, Heuck F, Neumann F, Tiling N, Pape UF, Plöckinger U, Wiedenmann B (2008) Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). J Clin Oncol 26:15s, suppl; abstr 14684
29. Anthony L, Chester M, Michael S, O'Dorisio TM, O'Dorisio MS (2008) Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer. J Clin Oncol 26:15s, suppl; abstr 14624
30. Phan AT, Yao JC, Fogelman DR, Hess KR, Ng CS, Bullock SA, Malinowski P, Regan E, Kulke M (2010) A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 28:7s, suppl; abstr 4001
31. Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525-537 (Pubitemid 40613318)
32. Karar J, Maity A (2011) PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4
33. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hind-gut, and unknown primary. Neuroendocrinology 95:157-176
34. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K (2011) RAD001 in advanced neuroendocrine tumors, third trial (RADI-ANT-3) study group. Everolimus for advanced pancreatic neuro-endocrine tumors. N Engl J Med 364(6):514-523
35. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangio-genic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407 (Pubitemid 28027321)
36. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592-603
37. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Anti-angiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Canc Cell 15 (3):220-231
38. Yao JC, Phan A (2011) Overcoming antiangiogenic resistance. Clin Cancer Res 17(16):5217-5219
39. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP et al (2009) Increased antitumor activity of bevaci-zumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8:1867-1877
40. Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X et al (2007) Molecular basis of the synergistic antiangiogenic activity of bev-acizumab and mithramycin. Cancer Res 67:4878-4885 (Pubitemid 46910196)
41. Allen E, Walters IB, Hanahan D (2011) Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 17:5299-5310
42. Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS (2011) A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Canc Chemother Pharmacol 68:293-300
43. Castellano DE, Capdevila J, Salazar R, Sastre J, Alonso V, Llanos M, Garcia-Carbonero R, Abad A, Sevilla I, Duran I (2011) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A a phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). J Clin Oncol 29:15s, suppl; abstr 4113
44. Yao JC, Phan AT, Fogleman D, Ng CS, Jacobs CB, Dagohoy CD, Leary C, Hess KR (2010) Randomized run-in study of bevacizu-mab (B) and everolimus (E) in low- to intermediate-grade neuro-endocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 28:15s, suppl; abstr 4002
45. Franco M, Pàez-Ribes M, Cortez E, Casanovas O, Pietras K (2011) Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res 43(12):884-889, Epub 2011 Sep 29